Indian pharmaceutical firm Zydus Lifesciences has unveiled Anyra, the country's first biosimilar Aflibercept 2 mg aimed at treating vision problems associated with conditions such as diabetic retinopathy and various retinal disorders. The action is crucial for enhancing national biologics capabilities and offering affordable, high-quality eye care solutions to India's population. The nation hosts 100 million individuals with diabetes, and the introduction of this biosimilar may be an effort to address the increasing need for retinal disorder treatments within the country. The new biosimilar is anticipated to enhance access to eye care options for the public by offering a cost-effective alternative to the current biologic medications available. The action is anticipated to enhance India’s status in the global biosimilar market and strengthen the nation's research abilities in the pharmaceutical field via local innovation in biosimilar medication development. Zydus Lifesciences has revealed a partnership with Regeneron and Bayer concerning the drug, possibly aiming to boost global collaborations in creating advanced therapeutics domestically. Zydus Lifesciences' initiative aims to enhance the emphasis of Indian pharmaceutical firms on advanced biologics and specialised solutions, potentially elevating the nation’s standing in the pharmaceutical industry in the future.